StageZero Life Sciences
  • About
    • Our Science >
      • The Sentinel Principle
    • Publications
    • Board of Directors
    • Partners
    • Scientific Advisory Board
  • Cancer Testing
    • Aristotle-Test
    • ColonSentry Test
    • Prostate Health Index
  • COVID-19 Testing
    • COVID-19 Travel Solutions
    • Return-to-Work
    • Return-to-Learn
    • COVID-19-ONSITE-TESTING
    • TESTS >
      • Covid-19-PCR-Saliva
      • Covid-19-PCR
      • Covid-19-Antibody
      • Respiratory Panel + COVID-19
    • Frequently Asked Questions
  • Physicians
    • Establish an Account
    • Order Supplies
    • Copia Login
  • INVESTORS
    • Investor Relations
    • Press Releases
    • Investor FAQs
    • Events
    • In the News
  • Contact
    • Customer Support
    • Corporate HQ
    • Careers
    • Bill Payment

Elevated PSA? You May Not Need a Prostate Biopsy

​​​While Prostate Specific Antigen (PSA) is currently the most used screening test for prostate cancer, it is widely recognized that PSA results can indicate the possibility of prostate cancer when none is present. Studies have shown that approximately 70% of men with an elevated PSA who have a biopsy do not have cancer.(1)

The Prostate Health Index (​phi ) Can Help Reduce Unnecessary Biopsies

The Prostate Health Index is an FDA approved blood test that can help differentiate prostate cancer from benign conditions in men with elevated PSA. ​The Prostate Health Index utilizes three different PSA markers (PSA, freePSA, and p2PSA) as part of a sophisticated algorithm to more reliably determine the probability of cancer in patients with elevated PSA levels and can help men and their physicians decide if a prostate biopsy is indicated. (2-5)

The Prostate Health Index is now available through the AVRT telehealth program. AVRT™ is a comprehensive telehealth program that uses advanced diagnostics, evidence based clinical protocols and online physician supervision to help patients stay well and reduce the risk of developing cancer and other chronic diseases. AVRT is run by The Care Oncology Group, a team of experienced doctors and cancer specialists who can help you understand early warning signals for cancer and chronic diseases.
    The Prostate Health Index can be ordered  through an AVRT Telehealth Physician

    Please complete the form below to get started.
Submit
Indications for use
​Male patients may be a candidate for the Prostate Index Test if they are age 50 years and older with an elevated PSA between 4ng/ml and 10ng/ml. Peer-reviewed published studies support the use of Prostate Health Index in men with total PSA values as low as 2 ng/ml (1-4). The Prostate Health Index is included in the National Comprehensive Cancer Network (NCCN) Guideline for Prostate Cancer Early Detection as a blood test to improve specificity for prostate cancer detection. (6)

Physician Enrollment

If you are a physician who would like to offer this test to patients in your practice, please click the enrollment button below to get started.
Enroll
Brochure

Additional Ordering Options

If you are a patient who would like to have your own physician order this test, please download our patient/physician discussion guide below to take to your next appointment.
Download Guide
References​
  1.  Biddle C, Brasel A, Underwood W 3rd, et al. Experiences of Uncertainty in Men With an Elevated PSA. Am J Mens Health. 2016;11(1):24-34.
  2. Catalona WJ, Partin AW, Sanda MG, et al. A Multi-Center Study of [−2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range. The Journal of Urology. 2011;185(5):1650-1655. 
  3. Loeb S, Sanda MG, Broyles DL, et al. The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. The Journal of Urology. 2015;193(4):1163-1169 
  4. Huang YQ, Sun T, Zhong WD, et al. Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. Am J Clin Exp Urol  2014;2(4):343-350 
  5. Lepor A, Catalona WJ, Loeb S. The Prostate Health Index: Its Utility In Prostate Cancer Detection. The Urologic Clinics of North America. 2016;43(1):1-6. 
  6. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Version 2.2018 – April 5, 2018 
Picture
StageZero Life Sciences. Ltd.
​30-70 East Beaver Creek Road
Richmond Hill, Ontario L4B 3B2

StageZero Life Sciences, Inc.
​8751 Park Central Drive, Suite 200
Richmond, VA 23227
​TEL: 855.420.7140 
Contact Information

Notice of Privacy Practices | Terms & Conditions | Privacy Statement & Policy | Licensing & Accreditation
  • About
    • Our Science >
      • The Sentinel Principle
    • Publications
    • Board of Directors
    • Partners
    • Scientific Advisory Board
  • Cancer Testing
    • Aristotle-Test
    • ColonSentry Test
    • Prostate Health Index
  • COVID-19 Testing
    • COVID-19 Travel Solutions
    • Return-to-Work
    • Return-to-Learn
    • COVID-19-ONSITE-TESTING
    • TESTS >
      • Covid-19-PCR-Saliva
      • Covid-19-PCR
      • Covid-19-Antibody
      • Respiratory Panel + COVID-19
    • Frequently Asked Questions
  • Physicians
    • Establish an Account
    • Order Supplies
    • Copia Login
  • INVESTORS
    • Investor Relations
    • Press Releases
    • Investor FAQs
    • Events
    • In the News
  • Contact
    • Customer Support
    • Corporate HQ
    • Careers
    • Bill Payment